Mantreda (Rivaroxaban)

Mantreda, a direct factor Xa inhibitor, is indicated for several thromboembolic conditions.

• Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism.
• Deep vein thrombosis (DVT): treats acute clot formation and facilitates resolution.
• Pulmonary embolism (PE): manages acute embolic events and prevents recurrence.
• Post‑operative thromboprophylaxis: lowers incidence of DVT and PE after hip or knee replacement surgery.

• Rivaroxaban selectively inhibits factor Xa in the coagulation cascade, blocking the conversion of prothrombin to thrombin. This reduces thrombin generation and fibrin clot formation, providing anticoagulant activity without requiring antithrombin as a cofactor. The inhibition is rapid, reversible, and dose‑dependent, offering predictable anticoagulation across a broad patient population.

Mantreda may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Bruising or minor bleeding at sites of injury.
• Nosebleeds.
• Headache.
• Mild gastrointestinal upset, such as nausea or dyspepsia.
• Diarrhea.
• Dizziness.

Serious or Rare Side Effects

• Major bleeding, including intracranial or gastrointestinal hemorrhage.
• Spinal or epidural hematoma, especially after neuraxial procedures.
• Significant liver enzyme elevations.
• Severe allergic reactions, such as rash or angioedema.
• Thrombocytopenia.
• Myocardial infarction.

Before prescribing Mantreda, clinicians should evaluate patient‑specific risk factors and monitor therapy.

• Renal function assessment: adjust use in patients with impaired clearance.
• Bleeding risk evaluation: avoid in active major bleeding.
• Concomitant strong CYP3A4 inhibitors: consider alternative therapy.
• Elderly patients: use caution due to increased bleeding susceptibility.
• Hepatic impairment: assess severity before use.
• Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Mantreda interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir).
• Dual antiplatelet agents (e.g., aspirin plus clopidogrel).
• Other anticoagulants (e.g., warfarin, heparin).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) at high doses.
• Certain antifungal agents (e.g., itraconazole).

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole).
• SSRIs or SNRIs that affect platelet function.
• Antacids that may alter absorption.
• Diuretics that affect renal clearance.
• Herbal supplements such as St. John’s wort.